Introduction
Studies in literature have shown that the rates of awareness of HPV vaccines & HIV preventive therapies, the rates of intent to use these and the rates of use of these therapies rose during the first few years of their introduction, but have fallen in subsequent years.
Various factors combine to determine the long term market access of any such service or therapies. Some of these factors are the societal beliefs, values and perceptions existing among the various stakeholders in that society.
The objective of this study is to assess the impact of social and behavioral factors on the acceptance and usage of HPV vaccines & HIV preventive therapy options such as Truvada for PrEP HIV.
We conducted extensive literature review to gather the views from various stake holders (Physicians, Beneficiaries, Press, Payers, Community including parents and community activists).
Methodology

Results
Case Study 1 -Societal views impacting market access of HPV vaccine in Europe
Case Study 2-Societal views impacting market access of HIV preventive therapies in US  Low coverage of the vaccine -Suboptimal vaccine usage rates have been observed and documented by ECDC  Discontinuation of HPV vaccination program in Romania  Prevailing safety concerns among the community have forced EMA to conduct a safety review References:1. Keller, et. al. (2011) . The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS (London, England), 25(18), 10.1097/QAD.0b013e32834d3cab. http://doi.org/10.1097/QAD.0b013e32834d3cab 2. Impact studies: Mathematical models -Cost-effectiveness studies. The market access of HPV vaccines has been impacted due to various diverse views prevailing in the society. Despite the strong clinical evidences and medical literature supporting the vaccine, the non supportive and unclear opinion of the stakeholders regarding the vaccines has led to the low adoption rate among the European population.
The market access of Truvada has been impacted due to mixed and unclear views among the various stakeholders in society. These views have, in turn, impacted the payers who are not willing to pay in spite of FDA's approval and recommendation for Truvada. The payers' unwillingness to pay has resulted in high co pays, shifting the cost towards the patients, and hence impacting access. 
Conclusion Conclusion
Overall Inference
The utilization of any medical service results from a number of related societal values and perceptions. This is especially relevant for drugs which challenge these well-held societal views. There are many and varied stakeholders and viewpoints to consider, e.g. deep seated beliefs, religious standpoints, social, economical and cultural view points of the stakeholders in society, as well as controversies over efficacy and safety, all having the ability to impact the acceptance and usage of any new therapy. As evident from the studied cases, in spite of the regulatory approval and national recommendations (often supported by strong clinical evidence), low adoption and high co-pays reflect that market access and uptake can be significantly driven by strong prevailing societal views that are not always grounded in a strong evidence base. 
